Prostate Cancer Therapeutics Market Set to Reach USD 37.92 Billion by 2035, growing at a CAGR of 10.06%

The U.S. prostate cancer therapeutics market is projected to reach $12.76 billion by 2035, while Europe is forecast to reach $10.46 billion. Growth is expected to be driven by radioligand therapies, PARP inhibitors and precision-oncology treatment approaches, signaling a favorable long-term outlook for companies serving prostate cancer care.

Analysis

This is a low-information market-sizing release rather than a near-term earnings catalyst; the projected endpoint is too distant to underwrite current multiples. The investable issue is share shift within metastatic castration-resistant prostate cancer: radioligand therapy can displace portions of chemotherapy and androgen-receptor inhibitor sequencing, while biomarker testing expands the addressable population for PARP combinations. Novartis (NVS) has the clearest radioligand exposure through Pluvicto, but capacity utilization, treatment-line label expansion, and referral-center throughput—not aggregate market growth—will determine revenue upside over the next 12-24 months.

Second-order beneficiaries include diagnostic and imaging suppliers that enable patient identification and treatment monitoring. Lantheus (LNTH), through PSMA PET imaging exposure, and Siemens Healthineers (SEMHF) / GE HealthCare (GEHC), through nuclear-medicine infrastructure, may capture earlier and potentially less binary demand than drug developers. Conversely, broader radioligand adoption raises execution risk for NVS: isotope supply, manufacturing slots, and specialized administration capacity can constrain sales despite clinical demand, creating openings for emerging competitors such as Telix Pharmaceuticals (TLX.AX) and POINT Biopharma assets now held by Eli Lilly (LLY).

Consensus may overvalue the headline TAM while underappreciating reimbursement and sequencing friction. PARP inhibitor growth for AstraZeneca (AZN) and Pfizer (PFE) remains dependent on testing rates and durable combination benefit; safety-related label restrictions or weaker real-world persistence could limit penetration. Over the next 1-3 months, watch NVS quarterly Pluvicto sales, manufacturing commentary, PSMA-PET procedure growth, and readouts/label actions from competing radiopharmaceutical programs; these are more actionable than long-dated market forecasts.

No broad sector trade is warranted solely from this release. A durable structural allocation requires evidence that radioligand capacity is expanding faster than treatment-center bottlenecks and that earlier-line use increases the treated population rather than merely reallocating existing oncology spend.

Key Decisions for Investors

• Maintain NVS on a catalyst watchlist rather than chase on TAM headlines; consider a 6-12 month long only after quarterly Pluvicto growth demonstrates supply-led acceleration and management confirms incremental manufacturing capacity. Thesis is falsified by sequential sales deceleration alongside stable demand commentary, indicating persistent delivery constraints.
• Monitor LNTH as a higher-purity diagnostic beneficiary: initiate only if PSMA-PET volume/reimbursement data confirm sustained double-digit procedure growth over the next two quarters. Risk/reward depends on imaging utilization converting into recurring scan volume; negative reimbursement changes or declining scan growth invalidate the setup.
• For a relative-value expression, evaluate long NVS versus short PFE only after validating relative prostate-cancer revenue exposure and valuation; NVS has radioligand upside, while PFE's PARP exposure faces greater biomarker-testing and class-competition sensitivity. Do not execute without current revenue-segmentation and borrow data.
• Set alerts around FDA label expansions, isotope-supply announcements, and competing radioligand trial data from LLY/TLX.AX over the next 6-18 months; a successful earlier-line competitor could compress NVS's expected peak-sales multiple even if the category grows.